Pieper A A, Verma A, Zhang J, Snyder S H
Department of Neuroscience, The Johns Hopkins University, School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, USA.
Trends Pharmacol Sci. 1999 Apr;20(4):171-81. doi: 10.1016/s0165-6147(99)01292-4.
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that is activated by DNA strand breaks to participate in DNA repair. Excessive activation of PARP, however, can deplete tissue stores of nicotinamide adenine dinucleotide (NAD), the PARP substrate which, with the resultant depletion of ATP, leads to cell death. In many cases of CNS damage, for example vascular stroke, nitric oxide release is a key stimulus to DNA damage and PARP activation. In conditions as diverse as focal cerebral ischaemia, myocardial infarction and toxin-induced diabetes, PARP inhibitors and PARP gene deletion afford dramatic protection from tissue damage. Accordingly, PARP inhibitors could provide novel therapeutic approaches in a wide range of clinical disorders.
聚(ADP - 核糖)聚合酶(PARP)是一种核酶,可被DNA链断裂激活以参与DNA修复。然而,PARP的过度激活会耗尽组织中的烟酰胺腺嘌呤二核苷酸(NAD)储备,NAD是PARP的底物,其导致的ATP耗竭会导致细胞死亡。在许多中枢神经系统损伤的情况下,例如血管性中风,一氧化氮的释放是DNA损伤和PARP激活的关键刺激因素。在诸如局灶性脑缺血、心肌梗死和毒素诱导的糖尿病等多种病症中,PARP抑制剂和PARP基因缺失可显著保护组织免受损伤。因此,PARP抑制剂可为多种临床疾病提供新的治疗方法。